1. Home
  2. MTA vs CTMX Comparison

MTA vs CTMX Comparison

Compare MTA & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Metalla Royalty & Streaming Ltd.

MTA

Metalla Royalty & Streaming Ltd.

HOLD

Current Price

$8.10

Market Cap

685.0M

Sector

N/A

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$4.13

Market Cap

596.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MTA
CTMX
Founded
1983
2008
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
685.0M
596.2M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
MTA
CTMX
Price
$8.10
$4.13
Analyst Decision
Hold
Strong Buy
Analyst Count
1
6
Target Price
$7.50
$6.50
AVG Volume (30 Days)
531.7K
2.8M
Earning Date
02-17-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
50.22
EPS
N/A
0.24
Revenue
$10,546,000.00
$113,631,000.00
Revenue This Year
$127.20
N/A
Revenue Next Year
$75.15
N/A
P/E Ratio
N/A
$17.20
Revenue Growth
108.91
N/A
52 Week Low
$2.52
$0.40
52 Week High
$8.63
$4.66

Technical Indicators

Market Signals
Indicator
MTA
CTMX
Relative Strength Index (RSI) 57.81 51.55
Support Level $7.49 $3.98
Resistance Level $8.30 $4.66
Average True Range (ATR) 0.33 0.28
MACD -0.05 -0.02
Stochastic Oscillator 53.07 34.16

Price Performance

Historical Comparison
MTA
CTMX

About MTA Metalla Royalty & Streaming Ltd.

Metalla Royalty & Streaming Ltd is a precious metals royalty and streaming company, which engages in the acquisition and management of precious metal royalties, streams, and similar production-based interests. It's a pure-play gold and silver streaming and royalty company. It generates revenue from royalties, streams, and other interests.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: